Jason D. Oliver

R&D Department, Alderley Park
Macclesfield, ENG SK104TF, United Kingdom

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 13 publications

Comment on: Antagonistic in vitro interaction between olorofim and voriconazole against Aspergillus fumigatus.

Comment on: Antagonistic in vitro interaction between olorofim and voriconazole against Aspergillus fumigatus.

Journal: The Journal of antimicrobial chemotherapy
Published: March 31, 2026

In vitro evaluation of olorofim and antifungal combinations against Aspergillus and Candida species.

In vitro evaluation of olorofim and antifungal combinations against Aspergillus and Candida species.

Journal: The Journal of antimicrobial chemotherapy
Published: May 13, 2025

Anti-Aspergillus activities of olorofim at sub-MIC levels during early-stage growth.

Anti-Aspergillus activities of olorofim at sub-MIC levels during early-stage growth.

Journal: Microbiology spectrum
Published: February 05, 2024

Characterisation of putative class 1A DHODH-like proteins from Mucorales and dematiaceous mould species.

Characterisation of putative class 1A DHODH-like proteins from Mucorales and dematiaceous mould species.

Journal: PloS one
Published: April 05, 2023

Aspergillus fumigatus strains that evolve resistance to the agrochemical fungicide ipflufenoquin in vitro are also resistant to olorofim.

Aspergillus fumigatus strains that evolve resistance to the agrochemical fungicide ipflufenoquin in vitro are also resistant to olorofim.

Journal: Nature microbiology
Published: February 23, 2023

Resistance profiling of Aspergillus fumigatus to olorofim indicates absence of intrinsic resistance and unveils the molecular mechanisms of acquired olorofim resistance.

Resistance profiling of Aspergillus fumigatus to olorofim indicates absence of intrinsic resistance and unveils the molecular mechanisms of acquired olorofim resistance.

Journal: Emerging microbes & infections
Published: February 03, 2022

The Dynamic Influence of Olorofim (F901318) on the Cell Morphology and Organization of Living Cells of Aspergillus fumigatus.

The Dynamic Influence of Olorofim (F901318) on the Cell Morphology and Organization of Living Cells of Aspergillus fumigatus.

Journal: Journal of fungi (Basel, Switzerland)
Published: February 29, 2020

Fluconazole Monotherapy Is a Suboptimal Option for Initial Treatment of Cryptococcal Meningitis Because of Emergence of Resistance.

Fluconazole Monotherapy Is a Suboptimal Option for Initial Treatment of Cryptococcal Meningitis Because of Emergence of Resistance.

Journal: mBio
Published: December 05, 2019

Madurella mycetomatis, the main causative agent of eumycetoma, is highly susceptible to olorofim.

Madurella mycetomatis, the main causative agent of eumycetoma, is highly susceptible to olorofim.

Journal: The Journal of antimicrobial chemotherapy
Published: September 13, 2019

Effect of the Novel Antifungal Drug F901318 (Olorofim) on Growth and Viability of Aspergillus fumigatus.

Effect of the Novel Antifungal Drug F901318 (Olorofim) on Growth and Viability of Aspergillus fumigatus.

Journal: Antimicrobial agents and chemotherapy
Published: February 06, 2018

A Nonredundant Phosphopantetheinyl Transferase, PptA, Is a Novel Antifungal Target That Directs Secondary Metabolite, Siderophore, and Lysine Biosynthesis in Aspergillus fumigatus and Is Critical for Pathogenicity.

A Nonredundant Phosphopantetheinyl Transferase, PptA, Is a Novel Antifungal Target That Directs Secondary Metabolite, Siderophore, and Lysine Biosynthesis in Aspergillus fumigatus and Is Critical for Pathogenicity.

Journal: mBio
Published: July 20, 2017

F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase.

F901318 represents a novel class of antifungal drug that inhibits dihydroorotate dehydrogenase.

Journal: Proceedings of the National Academy of Sciences of the United States of America
Published: October 30, 2016
Showing 1-12 of 13

Last Updated: 09/26/2026